1 / 1

Effect of Spironolactone on LV Hypertrophy in Chronic Renal Disease

Effect of Spironolactone on LV Hypertrophy in Chronic Renal Disease. LV: -14 g with spironolactone vs. 3 g with placebo (p < 0.01) PW velocity: -0.8 m/s vs. -0.1 m/s (p < 0.01) Systolic blood pressure: -11 mm Hg vs. -5 mm Hg (p < 0.05).

ricky
Download Presentation

Effect of Spironolactone on LV Hypertrophy in Chronic Renal Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Effect of Spironolactone on LV Hypertrophy in Chronic Renal Disease LV: -14 g with spironolactone vs. 3 g with placebo (p < 0.01) PW velocity: -0.8 m/s vs. -0.1 m/s (p < 0.01) Systolic blood pressure: -11 mm Hg vs. -5 mm Hg (p < 0.05) Trial design: After a 4-week run-in phase, patients with chronic renal disease were randomized to spironolactone (n = 56) versus placebo (n = 56) for 36 weeks. Results (p < 0.01) (p < 0.01) 3 -0.1 g m/sec Conclusions • Among patients with stage 2 or 3 chronic renal disease, the addition of spironolactone to ACE-I or ARB is beneficial • At 40 weeks, this therapy reduced LV mass, improved arterial stiffness, and reduced blood pressure -0.8 -14 Change in LV mass Change in PW velocity Spironolactone Placebo Edwards NC, et al. J Am Coll Cardiol 2009;54:505-12

More Related